Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cellulitis Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

NCT00829686
View directory record Official record
Conditions
Abscess
Interventions
Septra
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Not applicable Interventional Results available

Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess

NCT01498744
View directory record Official record
Conditions
Abscess Soft Tissue, Methicillin-resistant Staphylococcus Aureus (MRSA) Infection, Skin Abscess
Interventions
Oral Clindamycin
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Utility of Thermal Imaging in Diagnosis of Cellulitis for Lower Extremity Complaints in the Emergency Department

NCT04928235
View directory record Official record
Conditions
Cellulitis, Skin and Subcutaneous Tissue Infection
Interventions
Thermal Imaging as Diagnostic Adjunct
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees

NCT01105767
View directory record Official record
Conditions
Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections
Interventions
Chlorhexidine gluconate, Supplemental training, education and hygiene
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 42 Years · Male only
Enrollment
30,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional

Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas

NCT00295178
View directory record Official record
Conditions
Cellulitis
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Not applicable Interventional

The Use of Prophylactic Antibiotics in Isolated Blowout Fractures

NCT01504568
View directory record Official record
Conditions
Orbital Fractures, Orbital Cellulitis
Interventions
Treatment
Other
Lead sponsor
University of Arkansas
Other
Eligibility
5 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional Results available

Hospital Avoidance Strategies for ABSSSI

NCT03372941
View directory record Official record
Conditions
Skin Infection
Interventions
Dalbavancin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Hospitalization at Home: The Acute Care Home Hospital Program for Adults

NCT02864420
View directory record Official record
Conditions
Pneumonia, Heart Failure, Cellulitis, Urinary Tract Infections
Interventions
Home hospitalization, Inpatient Hospitalization
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT00865280
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
PTK 0796, linezolid, moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02127970
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
Dalbavancin, Dalbavancin-matching Placebo
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections

NCT01549613
View directory record Official record
Conditions
Cellulitis, Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

NCT01252719
View directory record Official record
Conditions
Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions
Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

NCT03637400
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Skin Infection
Interventions
TMP-SMX, DOXY
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
9 Years to 85 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Sylmar, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

NCT00730028
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Trimethoprim-sulfamethoxazole, Placebo, Clindamycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 85 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02570490
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
sodium fusidate, linezolid
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
12 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Anaheim, California • Bakersfield, California • Buena Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

NCT00366249
View directory record Official record
Conditions
Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions
Tigecycline, Ertapenem
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Los Angeles, California • Northridge, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

NCT00560599
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus Skin Infections
Interventions
mupirocin and chlorhexidine, household cleaning and disinfection, mupirocin, chlorhexidine, & household cleaning/disinfection
Drug · Behavioral
Lead sponsor
loren g miller
Other
Eligibility
1 Month and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Anaheim, California • Bellflower, California • Harbor City, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Teledermatology on Length of Hospital Admission, Length of Stay, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic ED Setting

NCT03036358
View directory record Official record
Conditions
Cellulitis
Interventions
teledermatology consult, Routine Care
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study Assessing the Impact of Dermatology Consultation in Patients Presenting With Possible Cellulitis

NCT01795092
View directory record Official record
Conditions
Cellulitis
Interventions
Dermatology Consultation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 22, 2026, 10:45 AM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

NCT00684177
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Ointment, 1%, Placebo ointment
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Months and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
32
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

NCT00442832
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
TD-1792, Vancomycin
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 22, 2026, 10:45 AM EDT